BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goncalves J, Myung G, Park M, Jeong D, Ghil J. SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis. Therap Adv Gastroenterol 2019;12:1756284819891081. [PMID: 31839806 DOI: 10.1177/1756284819891081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Kakiuchi T, Kimura S, Esaki M, Matsuo M. Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease. Front Pediatr 2021;9:670703. [PMID: 35004530 DOI: 10.3389/fped.2021.670703] [Reference Citation Analysis]
2 Gisbert JP, Gaffney K, Young D, Ebbers HC, Girolomoni G. Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective. Expert Opin Biol Ther 2021;:1-13. [PMID: 34918591 DOI: 10.1080/14712598.2022.2012146] [Reference Citation Analysis]
3 Bonek K, Roszkowski L, Massalska M, Maslinski W, Ciechomska M. Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells 2021;10:323. [PMID: 33557301 DOI: 10.3390/cells10020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Park SH, Park JC, Lukas M, Kolar M, Loftus EV. Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases. Intest Res 2020;18:34-44. [PMID: 32013313 DOI: 10.5217/ir.2019.09147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Solitano V, D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. Expert Rev Clin Immunol 2020;16:1019-28. [PMID: 32954893 DOI: 10.1080/1744666X.2021.1826311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Thomas PWA, Ferwerda G, West RL, Hoentjen F. Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn's Disease Patients: A Case Report and Review of the Literature. J Crohns Colitis 2021;15:162-4. [PMID: 32588044 DOI: 10.1093/ecco-jcc/jjaa115] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Moore GT, Keung C. Biosimilars: is interchangeability the proof of the pudding? Med J Aust 2021;214:124-5. [PMID: 33410132 DOI: 10.5694/mja2.50912] [Reference Citation Analysis]
9 Fousekis FS, Papamichael K, Kourtis G, Albani EN, Orfanidou A, Saridi M, Katsanos KH, Christodoulou DK. The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease. Ann Gastroenterol 2022;35:1-7. [PMID: 34987282 DOI: 10.20524/aog.2021.0682] [Reference Citation Analysis]